Ependymoma, Recurrent Active Not Recruiting Phase 2 Trials for Tipifarnib (DB04960)

Also known as: Ependymoma Recurrent / Recurrent Ependymoma

IndicationStatusPhase
DBCOND0106575 (Ependymoma, Recurrent)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04284774Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialTreatment